Review Article| Volume 36, ISSUE 4, P861-887, December 2022

Download started.


ICU Management of Invasive β-Hemolytic Streptococcal Infections


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Infectious Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Procop GW, Church DL, Hall GS, et al. Gram-Positive Cocci Part II: Streptococci, Enterococci, and the “Streptococcus-Like” Bacteria. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. Seventh ed: Wolters Kluwer.

        • Facklam R.
        What happened to the streptococci: overview of taxonomic and nomenclature changes.
        Clin Microbiol Rev. 2002; 15: 613-630
        • Lancefield R.C.
        J Exp Med. 1933; 57: 571-595
        • Brown J.H.
        The use of blood agar for the study of streptococci.
        The Rockefeller Institute for Medical Research, New York, N.Y.1919
        • Musher D.M.
        The Naming of Strep, with Apologies to T. S. Eliot.
        Clinical Infectious Diseases. 2009; 49: 1959-1960
        • Edwards M.S.
        • Baker C.J.
        Streptococcus agalactiae.
        in: Bennet John E. Dolin Raphael Blaser M.J. Mandell, Douglas, and Bennett’s Principle and Practice of Infectious Diseases. 2020
        • Broyles L.N.
        • Van Beneden C.
        • Beall B.
        • et al.
        Population-Based Study of Invasive Disease Due to β-Hemolytic Streptococci of Groups Other than A and B.
        Clinical Infectious Diseases. 2009; 48: 706-712
        • Babiker A.
        • Li X.
        • Lai Y.L.
        • et al.
        Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study.
        The Lancet Infectious diseases. 2020;
        • Ruoff K.L.
        Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen.
        Clin Microbiol Rev. 1988; 1: 102-108
        • Decker John P.
        • Ruoff Kathryn L.
        Classification of Streptocci.
        in: Mandell D. Bennetts Principles and Practice of Infectious Diseases. Elsevier, 2020
        • Walker M.J.
        • Barnett T.C.
        • McArthur J.D.
        • et al.
        Disease manifestations and pathogenic mechanisms of Group A Streptococcus.
        Clin Microbiol Rev. 2014; 27: 264-301
        • Bryant A.E.
        • Stevens D.L.
        Streptococcus pyogenes.
        in: Bennet J.E. Dolin R. Blaser M.J. Mandell, Douglas, and Bennett’s Principle and Practice of Infectious Diseases. 2020
        • Lindahl G.
        • Stålhammar-Carlemalm M.
        • Areschoug T.
        Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.
        Clin Microbiol Rev. 2005; 18: 102-127
        • Koskiniemi S.
        • Sellin M.
        • Norgren M.
        Identification of two genes, cpsX and cpsY, with putative regulatory function on capsule expression in group B streptococci.
        FEMS Immunol Med Microbiol. 1998; 21: 159-168
        • Brandt C.M.
        • Spellerberg B.
        Human infections due to Streptococcus dysgalactiae subspecies equisimilis.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009; 49: 766-772
        • Davies M.R.
        • McMillan D.J.
        • Beiko R.G.
        • et al.
        Virulence Profiling of Streptococcus dysgalactiae Subspecies equisimilis Isolated from Infected Humans Reveals 2 Distinct Genetic Lineages That Do Not Segregate with Their Phenotypes or Propensity to Cause Diseases.
        Clinical Infectious Diseases. 2007; 44: 1442-1454
        • Hashikawa S.
        • Iinuma Y.
        • Furushita M.
        • et al.
        Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome.
        Journal of clinical microbiology. 2004; 42: 186-192
        • Lother S.A.
        • Demczuk W.
        • Martin I.
        • et al.
        Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012-2014.
        Emerging infectious diseases. 2017; 23: 1079-1088
        • Ekelund K.
        • Skinhøj P.
        • Madsen J.
        • Konradsen H.B.
        Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects.
        Clinical Microbiology and Infection. 2005; 11: 569-576
        • Turner C.E.
        • Bubba L.
        • Efstratiou A.
        Pathogenicity Factors in Group C and G Streptococci.
        Microbiol Spectr. 2019; 7
        • Parks T.
        • Barrett L.
        • Jones N.
        Invasive streptococcal disease: a review for clinicians.
        Br Med Bull. 2015; 115: 77-89
      2. Centers for Disease Control and Prevention. Group A Streptococcal (GAS) Disease. 2018. (accessed Feb 7th 2022).

        • Kobayashi L.
        • Konstantinidis A.
        • Shackelford S.
        • et al.
        Necrotizing soft tissue infections: delayed surgical treatment is associated with increased number of surgical debridements and morbidity.
        J Trauma. 2011; 71: 1400-1405
        • Rantala S.
        • Vuopio-Varkila J.
        • Vuento R.
        • Huhtala H.
        • Syrjänen J.
        Clinical presentations and epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study.
        Clin Microbiol Infect. 2009; 15: 286-288
        • Lamagni T.L.
        • Neal S.
        • Keshishian C.
        • et al.
        Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004.
        Emerging infectious diseases. 2008; 14: 202-209
        • Stevens D.L.
        Invasive group A streptococcus infections.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1992; 14: 2-11
        • Steer A.C.
        • Lamagni T.
        • Curtis N.
        • Carapetis J.R.
        Invasive group a streptococcal disease: epidemiology, pathogenesis and management.
        Drugs. 2012; 72: 1213-1227
        • Tasher D.
        • Stein M.
        • Simões E.A.
        • Shohat T.
        • Bromberg M.
        • Somekh E.
        Invasive bacterial infections in relation to influenza outbreaks, 2006-2010.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011; 53: 1199-1207
        • Lappin E.
        • Ferguson A.J.
        Gram-positive toxic shock syndromes.
        The Lancet Infectious Diseases. 2009; 9: 281-290
        • Sablier F.
        • Slaouti T.
        • Drèze P.A.
        • et al.
        Nosocomial transmission of necrotising fasciitis.
        Lancet (London, England). 2010; 375: 1052
        • Lamagni T.L.
        • Oliver I.
        • Stuart J.M.
        Global Assessment of Invasive Group A Streptococcus Infection Risk in Household Contacts.
        Clinical Infectious Diseases. 2014; 60: 166-167
        • Carapetis J.R.
        • Jacoby P.
        • Carville K.
        • Ang S.J.
        • Curtis N.
        • Andrews R.
        Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014; 59: 358-365
        • Adebanjo T.
        • Apostol M.
        • Alden N.
        • et al.
        Evaluating Household Transmission of Invasive Group A Streptococcus Disease in the United States Using Population-based Surveillance Data.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020; 70 (2013-2016): 1478-1481
        • Prevention of Invasive Group A Streptococcal Infections Workshop Partcipants
        Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002; 35: 950-959
        • Robinson K.A.
        • Rothrock G.
        • Phan Q.
        • et al.
        Risk for severe group A streptococcal disease among patients' household contacts.
        Emerging infectious diseases. 2003; 9: 443-447
        • Raymond J.
        • Schlegel L.
        • Garnier F.
        • Bouvet A.
        Molecular characterization of Streptococcus pyogenes isolates to investigate an outbreak of puerperal sepsis.
        Infection control and hospital epidemiology. 2005; 26: 455-461
        • Turner C.E.
        • Dryden M.
        • Holden M.T.
        • et al.
        Molecular analysis of an outbreak of lethal postpartum sepsis caused by Streptococcus pyogenes.
        Journal of clinical microbiology. 2013; 51: 2089-2095
        • Daneman N.
        • McGeer A.
        • Low D.E.
        • et al.
        Hospital-Acquired Invasive Group A Streptococcal Infections in Ontario, Canada, 1992–2000.
        Clinical Infectious Diseases. 2005; 41: 334-342
        • Vannice K.
        • Ricaldi J.
        • Nanduri S.
        • et al.
        Streptococcus pyogenes pbp2x Mutation Confers Reduced Susceptibility to β-lactam antibiotics.
        Clinical Infectious Diseases. 2019;
      3. Centers for Disease Control and Prevention. Group B Strep (GBS) 2020. (accessed Feb 7th 2022).

        • Francois Watkins L.K.
        • McGee L.
        • Schrag S.J.
        • et al.
        Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016.
        JAMA Intern Med. 2019; 179: 479-488
      4. Centers for Disease Control and Prevention. ABCs Bact Facts interactive data dashboard: group B Streptococcus (2019). 2021. https://www-cdc-gov/abcs/bact-facts-interactive-dashboard.html (accessed April 6th 2022).

        • Jump R.L.P.
        • Wilson B.M.
        • Baechle D.
        • et al.
        Risk Factors and Mortality Rates Associated With Invasive Group B Streptococcus Infections Among Patients in the US Veterans Health Administration.
        JAMA Netw Open. 2019; 2e1918324
        • Jackson L.A.
        • Hilsdon R.
        • Farley M.M.
        • et al.
        Risk factors for group B streptococcal disease in adults.
        Ann Intern Med. 1995; 123: 415-420
        • Harris P.
        • Siew D.A.
        • Proud M.
        • Buettner P.
        • Norton R.
        Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period.
        Clin Microbiol Infect. 2011; 17: 1216-1222
        • Cohen-Poradosu R.
        • Jaffe J.
        • Lavi D.
        • et al.
        Group G streptococcal bacteremia in Jerusalem.
        Emerging infectious diseases. 2004; 10: 1455-1460
        • Rantala S.
        Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection.
        European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2014; 33: 1303-1310
        • Cunha C.B.
        Viridans Streptococci, Nutrionally Variant Streptococci, and Group C and G Streptococci.
        in: Bennet J.E. Dolin R. Blaser M.J. Mandell, Douglas, and Bennett’s Principle and Practice of Infectious Diseases. 2020
        • Centers for Disease Control and Prevention
        Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.
        MMWR Recomm Rep. 1997; 46: 1-55
        • Nelson G.E.
        • Pondo T.
        • Toews K.A.
        • et al.
        Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016; 63: 478-486
        • Stevens D.L.
        • Tanner M.H.
        • Winship J.
        • et al.
        Severe Group A Streptococcal Infections Associated with a Toxic Shock-like Syndrome and Scarlet Fever Toxin A.
        New England Journal of Medicine. 1989; 321: 1-7
      5. Centers for Disease Control and Prevention. Streptococcal Toxic Shock Syndrome. 2020. (accessed April 6th 2022)

        • Couture-Cossette A.
        • Carignan A.
        • Mercier A.
        • Desruisseaux C.
        • Valiquette L.
        • Pépin J.
        Secular trends in incidence of invasive beta-hemolytic streptococci and efficacy of adjunctive therapy in Quebec, Canada, 1996-2016.
        PloS one. 2018; 13: e0206289-e
        • Linner A.
        • Darenberg J.
        • Sjolin J.
        • Henriques-Normark B.
        • Norrby-Teglund A.
        Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014; 59: 851-857
        • Stevens D.L.
        • Bisno A.L.
        • Chambers H.F.
        • et al.
        Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America.
        Clinical Infectious Diseases. 2014; 59: 147-159
        • Wilson B.
        Necrotizing fasciitis.
        Am Surg. 1952; 18: 416-431
        • Johansson L.
        • Thulin P.
        • Low D.E.
        • Norrby-Teglund A.
        Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010; 51: 58-65
        • Bonne S.L.
        • Kadri S.S.
        Evaluation and Management of Necrotizing Soft Tissue Infections.
        Infect Dis Clin North Am. 2017; 31: 497-511
        • Alayed K.A.
        • Tan C.
        • Daneman N.
        Red Flags for Necrotizing Fasciitis: A Case Control Study.
        Int J Infect Dis. 2015; 36: 15-20
        • Kaul R.
        • McGeer A.
        • Low D.E.
        • Green K.
        • Schwartz B.
        Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study.
        Am J Med. 1997; 103: 18-24
        • Ward R.G.
        • Walsh M.S.
        Necrotizing fasciitis: 10 years' experience in a district general hospital.
        Br J Surg. 1991; 78: 488-489
      6. Centers for Disease Control and Prevention. Group A Streptococcal (GAS) Surveillance Report. 2019. (accessed Feb 7th 2022).

        • Stevens D.L.
        Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment.
        Emerging infectious diseases. 1995; 1: 69-78
        • Breiman R.F.
        • Davis J.P.
        • Facklam R.R.
        • et al.
        Defining the Group A Streptococcal Toxic Shock Syndrome: Rationale and Consensus Definition.
        Jama. 1993; 269: 390-391
        • Verani J.R.
        • McGee L.
        • Schrag S.J.
        Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.
        MMWR Recomm Rep. 2010; 59: 1-36
        • Kittang B.R.
        • Bruun T.
        • Langeland N.
        • Mylvaganam H.
        • Glambek M.
        • Skrede S.
        Invasive group A, C and G streptococcal disease in western Norway: virulence gene profiles, clinical features and outcomes.
        Clin Microbiol Infect. 2011; 17: 358-364
        • Woo P.C.
        • Fung A.M.
        • Lau S.K.
        • Wong S.S.
        • Yuen K.Y.
        Group G beta-hemolytic streptococcal bacteremia characterized by 16S ribosomal RNA gene sequencing.
        Journal of clinical microbiology. 2001; 39: 3147-3155
        • Nybakken E.J.
        • Oppegaard O.
        • Gilhuus M.
        • Jensen C.S.
        • Mylvaganam H.
        Identification of Streptococcus dysgalactiae using matrix-assisted laser desorption/ionization-time of flight mass spectrometry; refining the database for improved identification.
        Diagnostic Microbiology and Infectious Disease. 2021; 99: 115207
        • Rosa-Fraile M.
        • Spellerberg B.
        Reliable Detection of Group B Streptococcus in the Clinical Laboratory.
        Journal of clinical microbiology. 2017; 55: 2590-2598
        • Stevens D.L.
        • Bryant A.E.
        Necrotizing Soft-Tissue Infections.
        N Engl J Med. 2017; 377: 2253-2265
        • Wong C.H.
        • Khin L.W.
        • Heng K.S.
        • Tan K.C.
        • Low C.O.
        The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections.
        Critical care medicine. 2004; 32: 1535-1541
        • Hansen M.B.
        • Rasmussen L.S.
        • Svensson M.
        • et al.
        Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study.
        Sci Rep. 2017; 7: 42179
        • Sartelli M.
        • Guirao X.
        • Hardcastle T.C.
        • et al.
        2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections.
        World Journal of Emergency Surgery. 2018; 13: 58
        • Ramanan P.
        • Bryson A.L.
        • Binnicker M.J.
        • Pritt B.S.
        • Patel R.
        Syndromic Panel-Based Testing in Clinical Microbiology.
        Clin Microbiol Rev. 2017; 31 (e00024–17)
        • Hanson K.E.
        • Couturier M.R.
        Multiplexed Molecular Diagnostics for Respiratory, Gastrointestinal, and Central Nervous System Infections.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016; 63: 1361-1367
        • Rhodes A.
        • Evans L.E.
        • Alhazzani W.
        • et al.
        Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.
        Intensive care medicine. 2017; 43: 304-377
        • Kadri S.S.
        • Lai Y.L.
        • Warner S.
        • et al.
        Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.
        The Lancet Infectious diseases. 2021; 21: 241-251
        • Kumar A.
        • Roberts D.
        • Wood K.E.
        • et al.
        Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
        Critical care medicine. 2006; 34: 1589-1596
        • Nawijn F.
        • DPJ Smeeing
        • Houwert R.M.
        • Leenen L.P.H.
        • Hietbrink F.
        Time is of the essence when treating necrotizing soft tissue infections: a systematic review and meta-analysis.
        World Journal of Emergency Surgery. 2020; 15: 4
        • Vincent J.L.
        • Rello J.
        • Marshall J.
        • et al.
        International study of the prevalence and outcomes of infection in intensive care units.
        Jama. 2009; 302: 2323-2329
        • Mayr F.B.
        • Yende S.
        • Angus D.C.
        Epidemiology of severe sepsis.
        Virulence. 2014; 5: 4-11
        • Bryant A.E.
        • Bayer C.R.
        • Aldape M.J.
        • McIndoo E.
        • Stevens D.L.
        Emerging erythromycin and clindamycin resistance in group A streptococci: Efficacy of linezolid and tedizolid in experimental necrotizing infection.
        J Glob Antimicrob Resist. 2020; 22: 601-607
        • Oppegaard O.
        • Skrede S.
        • Mylvaganam H.
        • Kittang B.R.
        Emerging Threat of Antimicrobial Resistance in β-Hemolytic Streptococci.
        Front Microbiol. 2020; 11: 797
        • Hadeed G.J.
        • Smith J.
        • O'Keeffe T.
        • et al.
        Early surgical intervention and its impact on patients presenting with necrotizing soft tissue infections: A single academic center experience.
        J Emerg Trauma Shock. 2016; 9: 22-27
      7. V K, Hiremath BV, V A I. Necrotising soft tissue infection-risk factors for mortality. J Clin Diagn Res 2013; 7(8): 1662-1665.

        • Boyer A.
        • Vargas F.
        • Coste F.
        • et al.
        Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management.
        Intensive care medicine. 2009; 35: 847-853
        • Hakkarainen T.W.
        • Kopari N.M.
        • Pham T.N.
        • Evans H.L.
        Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes.
        Curr Probl Surg. 2014; 51: 344-362
        • Okoye O.
        • Talving P.
        • Lam L.
        • et al.
        Timing of Redébridement after Initial Source Control Impacts Survival in Necrotizing Soft Tissue Infection.
        The American Surgeon. 2013; 79: 1081-1085
        • Andreoni F.
        • Zurcher C.
        • Tarnutzer A.
        • et al.
        Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome.
        The Journal of infectious diseases. 2017; 215: 269-277
        • Eagle H.
        Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice.
        Am J Med. 1952; 13: 389-399
        • Stevens D.L.
        • Gibbons A.E.
        • Bergstrom R.
        • Winn V.
        The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.
        The Journal of infectious diseases. 1988; 158: 23-28
        • Zimbelman J.
        • Palmer A.
        • Todd J.
        Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.
        The Pediatric infectious disease journal. 1999; 18: 1096-1100
        • Mulla Z.D.
        • Leaverton P.E.
        • Wiersma S.T.
        Invasive group A streptococcal infections in Florida.
        Southern medical journal. 2003; 96: 968-973
        • Hamada S.
        • Nakajima M.
        • Kaszynski R.H.
        • et al.
        Association between adjunct clindamycin and in-hospital mortality in patients with necrotizing soft tissue infection due to group A Streptococcus: a nationwide cohort study.
        European Journal of Clinical Microbiology & Infectious Diseases. 2022; 41: 263-270
        • Bruun T.
        • Rath E.
        • Madsen M.B.
        • et al.
        Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021; 72: 293-300
        • Hamada S.
        • Nakajima M.
        • Kaszynski R.H.
        • et al.
        In-hospital mortality among patients with invasive non-group A β-hemolytic Streptococcus treated with clindamycin combination therapy: a nationwide cohort study.
        Acute medicine & surgery. 2021; 8: e634-e
        • Merino Díaz L.
        • Torres Sánchez M.J.
        • Aznar Martín J.
        Prevalence and mechanisms of erythromycin and clindamycin resistance in clinical isolates of β-haemolytic streptococci of Lancefield groups A, B, C and G in Seville, Spain.
        Clinical Microbiology and Infection. 2008; 14: 85-87
        • Compain F.
        • Hays C.
        • Touak G.
        • et al.
        Molecular characterization of Streptococcus agalactiae isolates harboring small erm(T)-carrying plasmids.
        Antimicrobial agents and chemotherapy. 2014; 58: 6928-6930
        • Haenni M.
        • Lupo A.
        • Madec J.Y.
        Antimicrobial Resistance in Streptococcus spp.
        Microbiol Spectr. 2018; 6
        • Fay K.
        • Onukwube J.
        • Chochua S.
        • et al.
        Patterns of Antibiotic Nonsusceptibility Among Invasive Group A Streptococcus Infections—United States, 2006–2017.
        Clinical Infectious Diseases. 2021; 73: 1957-1964
        • Nori P.
        • Nadeem N.
        • Saraiya N.
        • Szymczak W.
        • Boland-Reardon C.
        • Kahn M.
        Beta-hemolytic group a streptococcal orthopaedic infections: Our institutional experience and review of the literature.
        J Orthop. 2020; 21: 150-154
        • Coyle E.A.
        • Cha R.
        • Rybak M.J.
        Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release.
        Antimicrobial agents and chemotherapy. 2003; 47: 1752-1755
        • Rac H.
        • Bojikian K.D.
        • Lucar J.
        • Barber K.E.
        Successful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of Linezolid.
        Case Rep Infect Dis. 2017; 20175720708
        • Grebe T.
        • Hakenbeck R.
        Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics.
        Antimicrobial agents and chemotherapy. 1996; 40: 829-834
        • Musser J.M.
        • Beres S.B.
        • Zhu L.
        • et al.
        Reduced In Vitro Susceptibility of Streptococcus pyogenes to β-Lactam Antibiotics Associated with Mutations in the pbp2x Gene Is Geographically Widespread.
        Journal of clinical microbiology. 2020; 58
        • Fuursted K.
        • Stegger M.
        • Hoffmann S.
        • et al.
        Description and characterization of a penicillin-resistant Streptococcus dysgalactiae subsp. equisimilis clone isolated from blood in three epidemiologically linked patients.
        The Journal of antimicrobial chemotherapy. 2016; 71: 3376-3380
        • Metcalf B.J.
        • Chochua S.
        • Gertz Jr., R.E.
        • et al.
        Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA.
        Clin Microbiol Infect. 2017; 23 (e7-.e14): 574
        • Buter C.C.
        • Mouton J.W.
        • Klaassen C.H.
        • et al.
        Prevalence and molecular mechanism of macrolide resistance in beta-haemolytic streptococci in The Netherlands.
        Int J Antimicrob Agents. 2010; 35: 590-592
        • Gajdács M.
        • Ábrók M.
        • Lázár A.
        • Burián K.
        Beta-Haemolytic Group A, C and G Streptococcal Infections in Southern Hungary: A 10-Year Population-Based Retrospective Survey (2008-2017) and a Review of the Literature.
        Infect Drug Resist. 2020; 13: 4739-4749
        • Sriskandan S.
        • Ferguson M.
        • Elliot V.
        • Faulkner L.
        • Cohen J.
        Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
        The Journal of antimicrobial chemotherapy. 2006; 58: 117-124
        • Norrby-teglund A.
        • Ihendyane N.
        • Darenberg J.
        Intravenous Immunoglobulin Adjunctive Therapy in Sepsis, with Special Emphasis on Severe Invasive Group A Streptococcal Infections.
        Scandinavian Journal of Infectious Diseases. 2003; 35: 683-689
        • Mehta S.
        • McGeer A.
        • Low D.E.
        • et al.
        Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU.
        Chest. 2006; 130: 1679-1686
        • Parks T.
        • Wilson C.
        • Sriskandan S.
        • Curtis N.
        • Norrby-Teglund A.
        Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
        Clinical Infectious Diseases. 2018; 67: 1434-1436
        • Kaul R.
        • McGeer A.
        • Norrby-Teglund A.
        • et al.
        Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1999; 28: 800-807
        • Darenberg J.
        • Ihendyane N.
        • Sjölin J.
        • et al.
        Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003; 37: 333-340
        • Kadri S.S.
        • Swihart B.J.
        • Bonne S.L.
        • et al.
        Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.
        Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017; 64: 877-885
        • Madsen M.B.
        • Hjortrup P.B.
        • Hansen M.B.
        • et al.
        Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial.
        Intensive care medicine. 2017; 43: 1585-1593
        • Jallali N.
        • Withey S.
        • Butler P.E.
        Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis.
        Am J Surg. 2005; 189: 462-466
        • Bulger E.M.
        • Maier R.V.
        • Sperry J.
        • et al.
        A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
        JAMA Surgery. 2014; 149: 528-536
        • Arad G.
        • Levy R.
        • Nasie I.
        • et al.
        Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.
        PLoS Biol. 2011; 9e1001149
        • Ramachandran G.
        • Tulapurkar M.E.
        • Harris K.M.
        • et al.
        A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.
        The Journal of infectious diseases. 2013; 207: 1869-1877
        • Bulger E.M.
        • May A.
        • Dankner W.
        • Maislin G.
        • Robinson B.
        • Shirvan A.
        Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections.
        J Trauma Acute Care Surg. 2017; 83: 622-627
        • Bulger E.M.
        • May A.K.
        • Robinson B.R.H.
        • et al.
        A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103).
        Ann Surg. 2020; 272: 469-478
        • Nathens A.B.
        Commentary on "Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod.
        Ann Surg. 2020; 272: 479-480
        • Health Protection Agency; Group A Streptococcus Working Group
        Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease.
        Commun Dis Public Health. 2004; 7: 354-361
        • Allen U.
        • Moore D.
        Invasive group A streptococcal disease: Management and chemoprophylaxis.
        Paediatr Child Health. 2010; 15: 295-302
        • World Health Organization
        WHO recommendations for prevention and treatment of maternal peripartum infections.
        2015 (Geneva, Switzerland)
        • Onwuchuruba C.N.
        • Towers C.V.
        • Howard B.C.
        • Hennessy M.D.
        • Wolfe L.
        • Brown M.S.
        Transplacental passage of vancomycin from mother to neonate.
        Am J Obstet Gynecol. 2014; 210 (e1-.e4): 352
        • Dale J.B.
        • Walker M.J.
        Update on group A streptococcal vaccine development.
        Current opinion in infectious diseases. 2020; 33: 244-250
        • Davies M.R.
        • McIntyre L.
        • Mutreja A.
        • et al.
        Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.
        Nat Genet. 2019; 51: 1035-1043
        • Vekemans J.
        • Gouvea-Reis F.
        • Kim J.H.
        • et al.
        The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.
        Clinical Infectious Diseases. 2019; 69: 877-883
        • Sekuloski S.
        • Batzloff M.R.
        • Griffin P.
        • et al.
        Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.
        PLoS One. 2018; 13e0198658
        • Pastural É.
        • McNeil S.A.
        • MacKinnon-Cameron D.
        • et al.
        Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
        Vaccine. 2020; 38: 1384-1392
        • McNeil S.A.
        • Halperin S.A.
        • Langley J.M.
        • et al.
        A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults.
        International Congress Series. 2006; 1289: 303-306
        • Kobayashi M.
        • Schrag S.J.
        • Alderson M.R.
        • et al.
        WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.
        Vaccine. 2019; 37: 7307-7314
        • Carreras-Abad C.
        • Ramkhelawon L.
        • Heath P.T.
        • Le Doare K.
        A Vaccine Against Group B Streptococcus: Recent Advances.
        Infect Drug Resist. 2020; 13: 1263-1272
        • Buurman E.T.
        • Timofeyeva Y.
        • Gu J.
        • et al.
        A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
        The Journal of infectious diseases. 2019; 220: 105-115
        • Fischer P.
        • Pawlowski A.
        • Cao D.
        • et al.
        Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
        Vaccine. 2021; 39: 4489-4499
        • Carapetis J.R.
        • Steer A.C.
        • Mulholland E.K.
        • Weber M.
        The global burden of group A streptococcal diseases.
        The Lancet Infectious diseases. 2005; 5: 685-694
        • Babiker A.
        mSphere of Influence: Whole-Genome Sequencing, a Vital Tool for the Interruption of Nosocomial Transmission.
        mSphere. 2021; 6 (e00230–21)
        • Campbell A.J.
        • Dotel R.
        • Braddick M.
        • et al.
        Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trial.
        JAC Antimicrob Resist. 2022; 4: dlac014